PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New RSV vaccine for older adults can result in individual and societal cost savings, benefits

2024-09-05
(Press-News.org) Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

 

The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV vaccines: Arexvy, manufactured by GSK, and Abrysvo, manufactured by Pfizer. The study did not include a third approved vaccine, Moderna's mRESVIA.

 

The vaccines are now available to adults 60 and older. The CDC recommends a single dose for individuals over 75 and a single dose for those over 60 with increased risk of severe disease. The FDA in May 2023 approved both vaccines for use in older adults, a decision regarded by health care providers and public health experts as a substantial advancement in combating the illness. According to the U.S. Centers for Disease Control and Prevention, RSV results in 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths of adults 67 and older each year.

 

"We view this as a pivotal study that highlights the potential of RSV vaccination to make significant public health and economic impacts for older adults," said David Hutton, corresponding author of the study and professor of health management and policy and global public health at U-M's School of Public Health. 

 

Prior to the approval for vaccines in older adults, RSV immunizations were primarily recommended and used for high-risk infants. RSV is a common respiratory virus that can cause severe respiratory illness in young children, particularly those under a year old. 

 

"As RSV continues to pose a serious threat to individuals in this age group, the goal is for these findings to provide timely insights for healthcare decision-makers and policymakers," Hutton said.

 

To determine cost-effectiveness, Hutton and colleagues evaluated the general population within the 60 and older age group and recorded RSV-associated health care utilization, including outpatient appointments, emergency department visits, inpatient hospital stays and RSV deaths. 

 

The researchers specifically analyzed quality-adjusted life-years lost, or QALY, and societal costs that come with contracting RSV, and found the costs varied by age group and type of vaccine. The research also showed that vaccine efficacy, the incidence of RSV-related hospitalizations and vaccine costs had the most significant impact on the cost per QALY saved.

 

For example:

For all adults aged 60 and older, the societal cost per QALY saved was $196,842 for GSK's Arexvy and $176,557 for Pfizer's Abrysvo. For adults aged 65 and older, the cost was lower at $162,138 for GSK and $146,543 for Pfizer. For adults between 60 and 64, the cost per QALY saved was notably higher at $385,829 for GSK and $331,486 for Pfizer.  

Historically, efforts to prevent and treat RSV have focused on this younger population due to the high risk of hospitalization and severe outcomes. Recognizing similar risks for older populations, RSV vaccines were developed with the goal of preventing severe RSV-related illness, hospitalization and death. 

 

The researchers concluded that RSV vaccination might be cost-effective for adults 60 and older, especially those of more advanced age. They noted that reduced vaccine costs and sustained efficacy beyond two RSV seasons could make RSV vaccination more cost-effective for a broader population. They also said that uncertainties remain, particularly around long-term vaccine efficacy.

 

"We look forward to continuing working with CDC to determine the best ways to use our health resources to prevent respiratory disease," said Hutton, who also is a professor of operations and industrial engineering at the U-M College of Engineering.

 

Authors along with Hutton include: Lisa Prosser, Angela Rose and Kerra Mercon of the University of Michigan, and Ismael Ortega-Sanchez, Andrew Leidner, Fiona Havers, Mila Prill, Michael Whitaker, Lauren Roper, Jamison Pike, Amadea Britton and Michael Melgar of the CDC.

 

Study: Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus (DOI: 10.1016/j.vaccine.2024.126294)

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Research news from the Ecological Society of America

Research news from the Ecological Society of America
2024-09-05
The Ecological Society of America (ESA) presents a roundup of seven research articles recently published across its esteemed journals. Widely recognized for fostering innovation and advancing ecological knowledge, ESA’s journals consistently feature illuminating and impactful studies. This compilation of papers explores the impact of rising temperatures on pathogens, dynamics of predatory seabirds and their penguin prey in Antarctica, factors determining the speed of coral reef recovery from disturbance and more.   From Ecology: Some pathogens can’t ...

AI unlocks new path to personalized cancer treatments

AI unlocks new path to personalized cancer treatments
2024-09-05
Researchers at Auburn University, in collaboration with scientists from the University of Basel and ETH Zurich, have made a groundbreaking advance in the fight against cancer. The team, led by Dr. Rafael Bernardi, Associate Professor of Biophysics in the Department of Physics, has developed a novel approach integrating artificial intelligence (AI) with molecular dynamics simulations and network analysis to enhance the prediction of binding sites on the PD-L1 protein. This breakthrough promises to accelerate the development ...

ResearchGate and Mary Ann Liebert, Inc. announce journal home partnership for open access journals

2024-09-05
ResearchGate, the professional network for researchers, and Mary Ann Liebert, Inc., a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services, are pleased to announce a new partnership through ResearchGate’s innovative Journal Home offering. The partnership covers five Mary Ann Liebert, Inc. open access journals spanning the health and medical sciences. All backfile content and all new articles published with ...

Center for BrainHealth investigates the relationship between cannabis use, sleep and memory

Center for BrainHealth investigates the relationship between cannabis use, sleep and memory
2024-09-05
Dallas, September 5, 2024 – The growing legal use of recreational and medical cannabis has generated an increased concern for potential side effects from long-term use, particularly regarding problems with memory and sleep. Until now, the effect of cannabis use on sleep and on memory have only been studied separately. Research led by Francesca Filbey, PhD, from the Laboratory of Neuroimaging of Reward Dynamics at The University of Texas at Dallas’ Center for BrainHealth®, in collaboration with a team from the University of Amsterdam, aimed to fill this gap by testing how sleep impacts memory among cannabis users. The study, “The ...

K-State researchers determine molecular interactions in plants

2024-09-05
Plant scientists have long known that phosphorus is a crucial component in plant growth. A major discovery by a K-State biologist and her lab is leading to a better understanding of how plants detect and use that resource — potentially leading to more efficient production of crops for food, fiber and fuel. A team of researchers led by Kathrin Schrick, associate professor of biology, recently published this research in New Phytologist, a high-impact journal in the plant sciences. Schrick's lab focused on a specific transcription factor that regulates gene expression during development. They discovered a new kind of molecular interaction between the ...

Study estimates home blood pressure devices don’t fit properly for more than 17 million US adults

2024-09-05
Over-the-counter blood pressure measuring devices offer a simple, affordable way for people to track hypertension at home, but the standard arm-size ranges for these devices won’t appropriately fit millions of U.S. consumers, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers compared standard arm cuff size ranges for popular retail automatic blood pressure measuring devices to arm circumference data from U.S. government-sponsored national ...

Brain scans reveal that mindfulness meditation for pain is not a placebo

Brain scans reveal that mindfulness meditation for pain is not a placebo
2024-09-05
Pain is a complex, multifaceted experience shaped by various factors beyond physical sensation, such as a person’s mindset and their expectations of pain. The placebo effect, the tendency for a person’s symptoms to improve in response to inactive treatment, is a well-known example of how expectations can significantly alter a person’s experience. Mindfulness meditation, which has been used for pain management in various cultures for centuries, has long been thought to work by activating the placebo response. However, scientists have now ...

Cancer research in space for life on earth

2024-09-05
WINSTON-SALEM, N.C. – September 5, 2024 — The Wake Forest Institute for Regenerative Medicine (WFIRM) is honored to announce its selection for a pioneering cancer research project that will take place aboard the International Space Station (ISS). The project, one of only five chosen through a competitive solicitation by the ISS National Lab in partnership with NASA, aims to explore the effects of microgravity on cancer development and treatment. The project, led by Dr. Shay Soker, focuses on the use of organoids—miniature, simplified versions of organs grown in the lab from cells recovered from colorectal cancer patients. ...

Research spotlight: Radiology test can be used to diagnose immune checkpoint inhibitor-associated acute kidney injury

2024-09-05
How would you summarize your study for a lay audience? Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that have revolutionized the treatment of cancer. However, they can cause a wide variety of autoimmune toxicities, including immune checkpoint inhibitor-associated acute kidney injury (ICI-AKI). Differentiating ICI-AKI from acute kidney injury (AKI) due to alternative causes, which are common in cancer patients, is challenging without a kidney biopsy due to the risk of bleeding for some patients.  In this study, we ...

Rice’s Aryeh Warmflash awarded $1.6M NIH grant for research on early human development

Rice’s Aryeh Warmflash awarded $1.6M NIH grant for research on early human development
2024-09-05
Researchers at Rice University are working to understand how a single cell evolves into the complex network of specialized cells that form the human body. Funded by a $1.6 million grant from the National Institutes of Health, the research team’s new study could advance our knowledge of developmental disorders and contribute to the future of regenerative medicine. Led byAryeh Warmflash, an associate professor of biosciences and Cancer Prevention and Research Institute of Texas Scholar in cancer ...

LAST 30 PRESS RELEASES:

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

[Press-News.org] New RSV vaccine for older adults can result in individual and societal cost savings, benefits